Figure 5: Effects of tivozanib on activation of pertinent oncogenic pathways.

The cells were treated with tivozanib for 48 h then whole cell lysates were prepared and resolved by SDS PAGE. Samples were blotted for the phospho-form and re-probed for the respective total form of VEGFR2, STAT3, NF-κB p65, AKT and ERK1/2. β-actin was used as the loading control. The concentrations of tivozanib were 5, 10 and 20 μM. The blots are representative of three independent experiments with similar results.